Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Taps Regulus For microRNA Drug Development

This article was originally published in The Pink Sheet Daily

Executive Summary

Alnylam/Isis spinout Regulus nabs two high-profile partners for its microRNA platform by signing an agreement with AstraZeneca that includes a $28 million upfront payment and equity investment, and a separate deal with Biogen Idec.


Related Content

Flush With Cash And Partnered Up, Regulus Turns To Clinical Execution: An Interview With CEO Kleanthis Xanthopoulos
MicroRNA Momentum Builds, But Will Big Pharma Embrace It?
Deals Of The Week: AstraZeneca/Regulus, Biogen Idec/Regulus, Pfizer/AstraZeneca, Elan/Neotope
Biogen Turns In Robust Quarter, Fueled By Avonex; Late-Stage Commercial Catalysts Abound
Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus
GSK Doubles Up With Regulus, Signing New Collaboration For HCV Therapeutics
Regulus Is On The Launch “Platform” With $20M Series A Financing
Starlight Success: Isis, Alnylam Form Regulus To Develop MicroRNA Antagonists


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts